



**pan-Canadian Oncology Drug Review
Patient Advocacy Group Feedback on a pCODR
Expert Review Committee Initial
Recommendation**

**Obinutuzumab (Gazyva) for Chronic
Lymphocytic Leukemia**

**CLL Patient Advocacy Group (CLLPAG) and The
Leukemia & Lymphoma Society of Canada (LLSC)**

January 27, 2015

Feedback on pERC Initial Recommendation

Name of the drug indication(s): Obinutuzumab for Untreated CLL

Name of registered patient advocacy group: The Leukemia and Lymphoma Society of Canada and CLL Patient Advocacy Group

**pCODR may contact this person if comments require clarification. Contact information will not be included in any public posting of this document by pCODR.*

1.1 Comments on the Initial Recommendation

- a) Please indicate if the patient advocacy group agrees or disagrees with the initial recommendation:

agrees agrees in part disagree

pERC has done a good job of evaluating the use of Gazyva and chlorambucil in making the Initial Recommendation. They have recognized the need for less toxic drug regimes for the typical older CLL patient. The small sample size of patients who have used obinutuzumab were able to provide helpful information. Patient values were obviously considered in the initial recommendation. Funding of obinutuzumab will give older, less medically fit patients an improved choice for first line treatment. The Initial Recommendation Document and its components are clearly worded and the intent and reasons are easy to understand.

- b) Notwithstanding the feedback provided in part a) above, please indicate if the patient advocacy group would support this initial recommendation proceeding to final pERC recommendation (“early conversion”), which would occur within 2(two) business days of the end of the consultation period.

Support conversion to final recommendation. Do not support conversion to final recommendation.

Recommendation does not require reconsideration by pERC. Recommendation should be reconsidered by pERC.

- c) Please provide feedback on the initial recommendation. Is the initial recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

Page Number	Section Title	Paragraph, Line Number	Comments and Suggested Changes to Improve Clarity
			No comments

1.2 Comments Related to Patient Advocacy Group Input

Page Number	Section Title	Paragraph, Line Number	Comments related to initial patient advocacy group input
			No comments

1.3 Additional Comments About the Initial Recommendation Document

Page Number	Section Title	Paragraph, Line Number	Additional Comments
6	Patient based values	4 th paragraph, line 2/3	The patient submission noted that fatigue and low blood counts were the most common side effects not specifically red blood cell and platelets.